Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-19Clinical Trial Update: Modulating Oscillations and Working Memory in Patients With Subdural Electrodes [NA]
A UNC Chapel Hill clinical trial evaluating modulation of brain oscillations to improve working memory in epilepsy patients with subdural el…
-
FDA approval · 2026-03-18FDA Approved: TOPIRAMATE — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Topiramate by Ascend Laboratories, LLC.
-
FDA approval · 2026-03-18FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for Sabril (vigabatrin) submitted by Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Novadoz Pharmaceuticals LLC)
The FDA approved a supplemental application for Vigabatrin submitted by Novadoz Pharmaceuticals LLC.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for Vigabatrin by Amneal Pharmaceuticals NY LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Cipla USA, Inc.)
The FDA approved Cipla USA, Inc.'s supplemental application for Vigabatrin, resulting in an approved change to the labeling for the product.…
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Vigabatrin submitted by Zydus Lifesciences Limited. This action constitutes a supplemental appro…
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Edenbridge Pharmaceuticals LLC.)
FDA approved a supplemental application for Vigabatrin submitted by Edenbridge Pharmaceuticals LLC, authorizing the marketing of the generic…
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Hikma Pharmaceuticals USA Inc)
The FDA approved a supplemental application for Vigabatrin from Hikma Pharmaceuticals USA Inc., updating the drug's labeling.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for Vigabatrin from Par Health USA, LLC under the ANDA (ANDA208218). This action represents added re…
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for Vigabatrin submitted by Amneal Pharmaceuticals NY LLC.
-
FDA approval · 2026-03-18FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for SABRIL (vigabatrin) filed by Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Dr. Reddys Laboratories Inc.,)
FDA approved a supplemental application for Vigabatrin submitted by Dr. Reddys Laboratories Inc.
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Carnegie Pharmaceuticals LLC)
The FDA approved a supplemental application for Vigabatrin submitted by Carnegie Pharmaceuticals LLC.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Multicenter Pediatric Deep Brain Stimulation Registry
A multicenter pediatric deep brain stimulation registry sponsored by Boston Children's Hospital, evaluating DBS for dystonia, epilepsy and o…
-
FDA approval · 2026-03-18FDA Approved: VIGABATRIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Vigabatrin from Ascend Laboratories, LLC (ANDA 213375).
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy [NA]
This document provides an update on a Mayo Clinic–sponsored clinical trial investigating neurophysiologically based brain state tracking and…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
A multicenter retrospective survey is being conducted to delineate the molecular and phenotypic spectrum of epilepsy-dyskinesia syndromes in…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: Role of High-Frequency Oscillations on Scalp EEG in Identifying Epileptogenic Activity in Patients With Epilepsy and Healthy Controls
This trial update investigates whether high-frequency oscillations on scalp EEG can identify epileptogenic activity in patients with epileps…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies [NA]
A prospective study investigating postictal psychotic symptoms after video-EEG monitoring in focal epilepsy; the trial is not yet recruiting…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Neural Basis of Cognition [NA]
A Duke University-sponsored clinical trial is investigating the neural basis of cognition in epilepsy, with the study currently not yet recr…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans [NA]
A clinical trial is recruiting to study neural mechanisms of repetitive brain stimulation using invasive and noninvasive electrophysiology i…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Quality of Life Assessment in Patients With Epilepsy Using QOLIE-31
A clinical trial evaluating quality of life in people with epilepsy using the QOLIE-31 questionnaire; the study is not yet recruiting.
-
EMA approval · 2026-03-11EMA Authorised: Vimpat (lacosamide) — UCB Pharma SA
The European Medicines Agency granted authorisation for Vimpat (lacosamide) for epilepsy, with UCB Pharma SA as the marketing authorisation …
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Chinese-Specific Speech Imagery Coding Using High-Density ECoG [NA]
A clinical trial update indicates ongoing recruitment for a study on Chinese-specific speech imagery coding using high-density ECoG. The stu…